Company profile
BIOVIE INC.
NASDAQ:BIVIBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEZISTERIM | phase3 | — | 4 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04669028 | phase3 | completed | 2021-08-05 | 2023-09-30 | BioVie Inc. | A Phase 3 Study of NE3107 in Probable Alzheimer's Disease |
| NCT04112199 | phase2 | terminated | 2021-06-17 | 2023-05-08 | BioVie Inc. | A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites |
| NCT06757010 | phase2 | completed | 2025-03-26 | 2026-05-01 | BioVie Inc. | A Study of NE3107 in Early Parkinson's |
| NCT03107091 | phase2 | completed | 2017-07-15 | 2019-04-01 | BioVie Inc. | Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites |
| NCT05083260 | phase1_2 | completed | 2022-01-04 | 2022-11-21 | BioVie Inc. | NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa |
FDA applications (0)
No records yet.